{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T04:32:55Z","timestamp":1775104375947,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00210-025-04759-8","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T08:25:23Z","timestamp":1762763123000},"page":"5647-5661","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From bench to knowledge graph: mapping the global evolution of PD-1\/PD-L1 immunotherapy in gastric cancer"],"prefix":"10.1007","volume":"399","author":[{"given":"Yibo","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaotao","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaocong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuoqiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunsheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"4759_CR1","doi-asserted-by":"publisher","unstructured":"(2014) Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513:202-209. 20140723. https:\/\/doi.org\/10.1038\/nature13480","DOI":"10.1038\/nature13480"},{"key":"4759_CR2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","volume":"20","author":"JA Ajani","year":"2022","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ et al (2022) Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 20:167\u2013192. https:\/\/doi.org\/10.6004\/jnccn.2022.0008","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"4759_CR3","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.clon.2024.09.007","volume":"36","author":"MS Beshr","year":"2024","unstructured":"Beshr MS, Beshr IA, Al Hayek M et al (2024) PD-1\/PD-L1 inhibitors in combination with chemo or as monotherapy vs. chemotherapy alone in advanced, unresectable HER2-negative gastric, gastroesophageal junction, and esophageal adenocarcinoma: a meta-analysis. Clin Oncol (r Coll Radiol) 36(12):797\u2013808. https:\/\/doi.org\/10.1016\/j.clon.2024.09.007","journal-title":"Clin Oncol (r Coll Radiol)"},{"issue":"26","key":"4759_CR4","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQ et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455\u20132465. https:\/\/doi.org\/10.1056\/NEJMoa1200694","journal-title":"N Engl J Med"},{"key":"4759_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02085-w","volume":"23","author":"Y Chen","year":"2024","unstructured":"Chen Y, Jia K, Chong X et al (2024) Implications of PD-L1 expression on the immune microenvironment in HER2-positive gastric cancer. Mol Cancer 23:169. https:\/\/doi.org\/10.1186\/s12943-024-02085-w","journal-title":"Mol Cancer"},{"key":"4759_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01581-2","volume":"17","author":"W Cheng","year":"2024","unstructured":"Cheng W, Kang K, Zhao A et al (2024) Dual blockade immunotherapy targeting PD-1\/PD-L1 and CTLA-4 in lung cancer. J Hematol Oncol 17:54. https:\/\/doi.org\/10.1186\/s13045-024-01581-2","journal-title":"J Hematol Oncol"},{"key":"4759_CR7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.5230\/jgc.2025.25.e4","volume":"25","author":"Y Cho","year":"2025","unstructured":"Cho Y, Ahn S, Kim KM (2025) PD-L1 as a biomarker in gastric cancer immunotherapy. J Gastric Cancer 25:177\u2013191. https:\/\/doi.org\/10.5230\/jgc.2025.25.e4","journal-title":"J Gastric Cancer"},{"key":"4759_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01800-3","volume":"22","author":"X Chu","year":"2023","unstructured":"Chu X, Tian W, Wang Z et al (2023) Co-inhibition of TIGIT and PD-1\/PD-L1 in cancer immunotherapy: mechanisms and clinical trials. Mol Cancer 22:93. https:\/\/doi.org\/10.1186\/s12943-023-01800-3","journal-title":"Mol Cancer"},{"key":"4759_CR9","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","volume":"18","author":"DB Doroshow","year":"2021","unstructured":"Doroshow DB, Bhalla S, Beasley MB et al (2021) PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol 18:345\u2013362. https:\/\/doi.org\/10.1038\/s41571-021-00473-5","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"4759_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01654-2","volume":"18","author":"Y Duan","year":"2025","unstructured":"Duan Y, Xu Y, Dou Y et al (2025) Helicobacter pylori and gastric cancer: mechanisms and new perspectives. J Hematol Oncol 18(1):10. https:\/\/doi.org\/10.1186\/s13045-024-01654-2","journal-title":"J Hematol Oncol"},{"key":"4759_CR11","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1158\/2326-6066.Cir-24-1179","volume":"13","author":"M Fang","year":"2025","unstructured":"Fang M, Li Y, Wang P et al (2025) Mettl3 inhibition restores PD-L1 expression and CD8+ T-cell cytotoxic function in immunotherapy-treated gastric cancer. Cancer Immunol Res 13:1037\u20131052. https:\/\/doi.org\/10.1158\/2326-6066.Cir-24-1179","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"4759_CR12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0013","volume":"4","author":"CS Fuchs","year":"2018","unstructured":"Fuchs CS, Doi T, Jang RW et al (2018) Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol 4(5):e180013. https:\/\/doi.org\/10.1001\/jamaoncol.2018.0013","journal-title":"JAMA Oncol"},{"key":"4759_CR13","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","volume":"600","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Kawazoe A, Ya\u00f1ez P et al (2021a) The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature 600:727\u2013730. https:\/\/doi.org\/10.1038\/s41586-021-04161-3","journal-title":"Nature"},{"key":"4759_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M et al (2021b) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398:27\u201340. https:\/\/doi.org\/10.1016\/s0140-6736(21)00797-2","journal-title":"Lancet"},{"key":"4759_CR15","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3322\/caac.21657","volume":"71","author":"SS Joshi","year":"2021","unstructured":"Joshi SS, Badgwell BD (2021) Current treatment and recent progress in gastric cancer. CA Cancer J Clin 71:264\u2013279. https:\/\/doi.org\/10.3322\/caac.21657","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"4759_CR16","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/s1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang YK, Chen LT, Ryu MH et al (2022) Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 23(2):234\u2013247. https:\/\/doi.org\/10.1016\/s1470-2045(21)00692-6","journal-title":"Lancet Oncol"},{"key":"4759_CR17","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1158\/1055-9965.Epi-13-1057","volume":"23","author":"P Karimi","year":"2014","unstructured":"Karimi P, Islami F, Anandasabapathy S et al (2014) Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev 23:700\u2013713. https:\/\/doi.org\/10.1158\/1055-9965.Epi-13-1057","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"4759_CR18","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","volume":"24","author":"ST Kim","year":"2018","unstructured":"Kim ST, Cristescu R, Bass AJ et al (2018) Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med 24:1449\u20131458. https:\/\/doi.org\/10.1038\/s41591-018-0101-z","journal-title":"Nat Med"},{"key":"4759_CR19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.canlet.2021.06.007","volume":"518","author":"V Koh","year":"2021","unstructured":"Koh V, Chakrabarti J, Torvund M et al (2021) Hedgehog transcriptional effector GLI mediates mTOR-induced PD-L1 expression in gastric cancer organoids. Cancer Lett 518:59\u201371. https:\/\/doi.org\/10.1016\/j.canlet.2021.06.007","journal-title":"Cancer Lett"},{"key":"4759_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1625259","volume":"12","author":"J Leng","year":"2025","unstructured":"Leng J, Liu M, Wang Q et al (2025) Neoadjuvant PD-1\/PD-L1 inhibitors combined with chemotherapy in gastric cancer and gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis of single-arm studies. Front Med 12:1625259. https:\/\/doi.org\/10.3389\/fmed.2025.1625259","journal-title":"Front Med"},{"key":"4759_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114838","volume":"244","author":"D Li","year":"2022","unstructured":"Li D, Yu D, Li Y et al (2022) A bibliometric analysis of PROTAC from 2001 to 2021. Eur J Med Chem 244:114838. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114838","journal-title":"Eur J Med Chem"},{"key":"4759_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-02515-1","volume":"16","author":"BY Li","year":"2025","unstructured":"Li BY, Li HL, Zeng FE et al (2025) Identification of PD-L1-related biomarkers for selecting gastric adenocarcinoma patients for PD-1\/PD-L1 inhibitor therapy. Discover Oncol 16:689. https:\/\/doi.org\/10.1007\/s12672-025-02515-1","journal-title":"Discover Oncol"},{"key":"4759_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.731798","volume":"12","author":"J Liu","year":"2021","unstructured":"Liu J, Chen Z, Li Y et al (2021) PD-1\/PD-L1 checkpoint inhibitors in tumor immunotherapy. Front Pharmacol 12:731798. https:\/\/doi.org\/10.3389\/fphar.2021.731798","journal-title":"Front Pharmacol"},{"key":"4759_CR24","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2024.39.e176","volume":"39","author":"KD Min","year":"2024","unstructured":"Min KD, Baek YJ, Hwang K et al (2024) Fine-scale spatial prediction on the risk of Plasmodium vivax infection in the Republic of Korea. J Korean Med Sci 39:e176. https:\/\/doi.org\/10.3346\/jkms.2024.39.e176","journal-title":"J Korean Med Sci"},{"issue":"6","key":"4759_CR25","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/s1470-2045(16)00175-3","volume":"17","author":"K Muro","year":"2016","unstructured":"Muro K, Chung HC, Shankaran V et al (2016) Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol 17(6):717\u2013726. https:\/\/doi.org\/10.1016\/s1470-2045(16)00175-3","journal-title":"Lancet Oncol"},{"issue":"21","key":"4759_CR26","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1200\/jco.2015.64.8931","volume":"34","author":"R Nanda","year":"2016","unstructured":"Nanda R, Chow LQ, Dees EC et al (2016) Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. J Clin Oncol 34(21):2460\u20132467. https:\/\/doi.org\/10.1200\/jco.2015.64.8931","journal-title":"J Clin Oncol"},{"key":"4759_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2022.100907","volume":"66","author":"K Pang","year":"2023","unstructured":"Pang K, Shi ZD, Wei LY et al (2023) Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1\/PD-L1 blockade. Drug Resist Updat 66:100907. https:\/\/doi.org\/10.1016\/j.drup.2022.100907","journal-title":"Drug Resist Updat"},{"key":"4759_CR28","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s40259-020-00428-9","volume":"34","author":"JR Patrinely Jr","year":"2020","unstructured":"Patrinely JR Jr, Dewan AK, Johnson DB (2020) The role of anti-PD-1\/PD-L1 in the treatment of skin cancer. BioDrugs 34:495\u2013503. https:\/\/doi.org\/10.1007\/s40259-020-00428-9","journal-title":"BioDrugs"},{"key":"4759_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1566939","volume":"16","author":"W Pu","year":"2025","unstructured":"Pu W, Li S, Zhang J et al (2025) The efficacy and safety of PD-1\/PD-L1 inhibitors in combination with chemotherapy as a first-line treatment for unresectable, locally advanced, HER2-negative gastric or gastroesophageal junction cancer: a meta-analysis of randomized controlled trials. Front Immunol 16:1566939. https:\/\/doi.org\/10.3389\/fimmu.2025.1566939","journal-title":"Front Immunol"},{"key":"4759_CR30","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41586-022-04508-4","volume":"603","author":"K Shitara","year":"2022","unstructured":"Shitara K, Ajani JA, Moehler M et al (2022) Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature 603:942\u2013948. https:\/\/doi.org\/10.1038\/s41586-022-04508-4","journal-title":"Nature"},{"key":"4759_CR31","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/s0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, Nilsson M, Grabsch HI et al (2020) Gastric cancer. Lancet 396:635\u2013648. https:\/\/doi.org\/10.1016\/s0140-6736(20)31288-5","journal-title":"Lancet"},{"key":"4759_CR32","doi-asserted-by":"publisher","DOI":"10.1177\/1010428317714626","volume":"39","author":"Z Song","year":"2017","unstructured":"Song Z, Wu Y, Yang J et al (2017) Progress in the treatment of advanced gastric cancer. Tumour Biol 39:1010428317714626. https:\/\/doi.org\/10.1177\/1010428317714626","journal-title":"Tumour Biol"},{"key":"4759_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceca.2019.06.007","volume":"82","author":"AM Sterea","year":"2019","unstructured":"Sterea AM, Egom EE, El Hiani Y (2019) TRP channels in gastric cancer: new hopes and clinical perspectives. Cell Calcium 82:102053. https:\/\/doi.org\/10.1016\/j.ceca.2019.06.007","journal-title":"Cell Calcium"},{"key":"4759_CR34","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"4759_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104623","volume":"152","author":"R Xu","year":"2020","unstructured":"Xu R, Wu J, Zhang X et al (2020) Modified Bu-zhong-yi-qi decoction synergies with 5 fluorouracile to inhibits gastric cancer progress via PD-1\/PD-L1-dependent T cell immunization. Pharmacol Res 152:104623. https:\/\/doi.org\/10.1016\/j.phrs.2019.104623","journal-title":"Pharmacol Res"},{"key":"4759_CR36","doi-asserted-by":"publisher","first-page":"899","DOI":"10.21037\/jgo-24-824","volume":"16","author":"L Xu","year":"2025","unstructured":"Xu L, Li Y, Wang K et al (2025) D-dimer predicts the response of patients with gastric cancer to first-line immunotherapy combined with chemotherapy. J Gastrointest Oncol 16:899\u2013908. https:\/\/doi.org\/10.21037\/jgo-24-824","journal-title":"J Gastrointest Oncol"},{"key":"4759_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1636288","volume":"13","author":"W Zhou","year":"2025","unstructured":"Zhou W, Cai ZZ, Fan Z et al (2025) PD-L1 expression predicts the efficacy of PD-1 blockade plus chemotherapy versus chemotherapy alone in treatment-na\u00efve advanced or metastatic gastric cancer: a pooled analysis of reconstructed individual patient-level data from two randomized trials. Front Cell Dev Biol 13:1636288. https:\/\/doi.org\/10.3389\/fcell.2025.1636288","journal-title":"Front Cell Dev Biol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04759-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04759-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04759-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T03:06:17Z","timestamp":1775099177000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04759-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4759"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04759-8","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"19 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This manuscript is not a clinical trial, hence the ethics approval and consent to participation are not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participation"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}]}}